ArticleJournal of translational medicine2013

A first-in-human, phase 1, dose-escalation study of dinaciclib, a novel cyclin-dependent kinase inhibitor, administered weekly in subjects with advanced malignancies.

John J Nemunaitis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.